Drugs, money and society (part II)

British Journal of Clinical Pharmacology

Volumn 70, Issue 3, 2010, Pages 342-345

  Walley, Tom ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Effectiveness; Efficiency; Pharmacoeconomics

Indexed keywords

BORTEZOMIB; DRUG;

CLINICAL PHARMACOLOGY; COST; COST EFFECTIVENESS ANALYSIS; CURRICULUM; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; EVIDENCE BASED MEDICINE; GOVERNMENT; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICE; MARKETING; MEDICAL PRACTICE; MONEY; NATIONAL HEALTH SERVICE; PHARMACIST; PRIORITY JOURNAL; PROSPECTIVE PRICING; QUALITY ADJUSTED LIFE YEAR; RESPONSIBILITY; SHORT SURVEY; SOCIETY; UNITED KINGDOM;

DRUG COSTS; ECONOMICS, PHARMACEUTICAL; GOVERNMENT AGENCIES; GREAT BRITAIN; HUMANS; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES AS TOPIC;

EID: 77955719861     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03569.x     Document Type: Short Survey

References (19)

1. Hiatt HH. Protecting the medical commons: who is responsible? N Engl J Med 1975 293 : 235 241.
2. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London : Royal Society of Medicine, 1999.
3. Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, Kinosian B, Schwartz JS. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991 324 : 1362 1365.
4. Kassirer JP, Angell M. The journal's policy on cost-effectiveness analyses. N Engl J Med 1994 331 : 669 670.
5. Sacristán JA, Bolaños E, Hernández JM, Soto J, Galende I. Publication bias in health economic studies. Pharmacoeconomics 1997 11 : 289 292.
6. Walley T, Edwards RT. Is there a need for an independent centre for pharmacoeconomics in the UK? Pharmacoeconomics 1994 5 : 93 100.
7. Walley T. Drugs, money and society. Br J Clin Pharmacol 1995 39 : 343 345.
8. Walley T, Davey P. Pharmacoeconomics: a challenge for clinical pharmacologists. Br J Clin Pharmacol 1995 40 : 199 202.
9. Rawlins MD. The decade of NICE. Lancet 2009 374 : 351 352.
10. Maynard A, Bloor K. NICE wobbles. J R Soc Med 2009 102 : 212 213.
11. Walley T. Prescribing of neuropsychotherapeutics in the UK; what has been the impact of NICE? CNS Drugs 2004 18 : 1 12.
12. Breckenridge A, Walley T. Risk sharing and payment by results. Clin Pharmacol Ther 2008 83 : 666 667.
13. Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. An OFT Market Study. London : Office of Fair Trading, 2007. Available at http://www.oft.gov.uk/shared-oft/reports/comp-policy/oft885.pdf (last accessed K, Briggs A, Buxton MJ, Culyer AJ, McCabe C, Walker S, Sculpher MJ. Value based pricing for NHS drugs: an opportunity not to be missed? BMJ 2008 336 : 251 254.
14. Pizzi L, Singh V. Pharmacoeconomics is coming of age. Clin Pharmacol Ther 2008 84 : 188 190.
15. Rawlins M, Barnett D. NICE at ten. Pharmacology Matters 2009 2 : 6 7.
16. Walley T, Breckenridge A. Pharmacoeconomics comes of age. Clin Pharmacol Ther 2008 84 : 279 280.
17. Williams A. Cost-benefit analysis: bastard science? and/or insidious poison in the body politick? J Public Econ 1972 1 : 199 225.
18. Horton R. Pharmacoeconomical with the truth. Lancet 1993 341 : 752.
19. Horton R. NICE vindicated in UK's High Court. Lancet 2007 370 : 547 548.